ClinicalTrials.gg
CompletedNCT05158335Updated Aug 9, 2023

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects

A Phase 1 interventional study of MBX 2109 (Part A) and MBX 2109 (Part B) in Healthy, sponsored by MBX Biosciences. Completed at 2 sites in United States. Open to participants aged 21 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-09.

Sponsored by MBX Biosciences · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jun 2023, 3 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
21 Years to 60 Years
Sex
All
01

Study summary

The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of MBX 2109 in healthy volunteers.

This study includes 2 parts. Part A involves a single dose of MBX 2109 taken as a subcutaneous (SC) injection just under the skin. Part B involves repeat doses of MBX 2109 taken as a SC injection just under the skin. Each participant will enroll in only one part.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

MBX Biosciences is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy men and women (of nonchildbearing potential) between 20 and 60 years of age, inclusive.
  2. between 20.0 and 32.0 kg/m2, inclusive.
  3. No findings on physical examination, , laboratory tests or vital signs
  4. Subject has been given signed

Exclusion criteria

Exclusion Criteria:

  1. History of any significant illness or disorder
  2. Acute illness within 30 days of administration of first dose of study drug
  3. Positive screening result for , or
  4. History of or current substance abuse (drug or alcohol) within past 1 year or positive test for drugs of abuse during screening
  5. Use of nicotine-containing or vaping products within 3 months prior to screening or check-in
  6. Use of cannabis within 45 days prior to check-in
  7. Donation of blood within 3 months prior to screening, plasma within 2 weeks prior to screening or within 6 weeks prior to screening
  8. Participation in any other study drug trial in which receipt of an investigational study drug occurred within past 30 days
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    MBX 2109 (Part A)

    Single ascending SC doses

    Drug: MBX 2109 (Part A)

  • Experimental
    MBX 2109 (Part B)

    Repeated ascending SC doses

    Drug: MBX 2109 (Part B)

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Single ascending SC dose of MBX 2109: 50 µg, 150 µg, 300 µg, 460 µg, 600 µg

  • Repeated ascending SC doses of MBX 2109: 200 µg, 300 µg, 460 µg, 600 µg, 900 µg

  • DrugPlacebo

    Single SC dose or repeated SC doses of placebo.

06

What researchers measure

Primary outcomes

  1. Primary Outcome Measures

    Number of participants with adverse events (AEs) or Serious Adverse Events (SAEs)

    Time frame: Baseline through Day 40 (part A) or Day 60 (Part B)

Secondary outcomes

  1. Secondary Outcome Measures 1

    Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of MBX 2109

    Time frame: Baseline through Day 40 (part A) or Day 60 (Part B)

  2. Secondary Outcome Measures 2

    Pharmacodynamics (PD): change from baseline in albumin corrected serum calcium

    Time frame: Baseline through Day 40 (part A) or Day 60 (Part B)

07

Study locations

2 sites
  • Labcorp Drug Development: Clinical Research Unit
    Dallas, Texas 75247, United States
  • Labcorp Drug Development: Clinical Research Unit
    Madison, Wisconsin 53704, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Jun 2023, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2021
First posted
Dec 15, 2021
StartActual
Nov 10, 2021
Primary completionActual
Jun 20, 2023
CompletionActual
Jun 20, 2023
Last update
Aug 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05158335
Lead sponsor
MBX Biosciences
Responsible party
Sponsor
First posted
Dec 15, 2021
Start date
Nov 10, 2021
Primary completion
Jun 20, 2023
Completion
Jun 20, 2023
Last update
Aug 9, 2023

Study contacts

Mary Jane Geiger, MD, PhD
study director · MBX Biosciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Canvuparatide

Start the discussion